Dose-related Endocrine Effects and Pharmacokinetics of Oral and Intramuscular 4-Hydroxyandrostenedione in Postmenopausal Breast Gmcer Patients

Cancer Research

Volumn 49, Issue 5, 1989, Pages 1306-1312

  Dowsett, M ^a   Cunningham, D C ^b   Stein, R C ^b   Evans, S ^a   Dehennin, L ^c   Hedley, A ^b   Coombes, R C ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c Fondation de Rech en Hormonologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYANDROSTENEDIONE;

BREAST CANCER; CLINICAL ARTICLE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANDROSTENEDIONE; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTRONE; FEMALE; HALF-LIFE; HUMAN; INJECTIONS, INTRAMUSCULAR; MENOPAUSE; SEX HORMONE-BINDING GLOBULIN;

EID: 0024595623     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Santen, R. J., Santner, S., Davis, B., Veldhuis, J., Samojlik, E., and Ruby, E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J. Cin. Endocrinol. Metab., 47: 1257-1265,1978.
2. Harris, A. L., Dowsett, M., Smith, I. E., and Jeffcoate, S. L. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br. J. Cancer, 47:621-627,1983.
3. Stuart-Harris, R., Dowsett, M., D'Souza, A., Donaldson, A., Harris, A. L., Jeffcoate, S. L., and Smith, I. E. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer. Clin. Endocrinol., 22:219-226,1985.
4. Cohen, M. P. Aminoglutethimide inhibition of adrenal desmolase activity. Proc. Soc. Exp. Biol. Med., 127:1086-1090,1969.
5. Touitou, Y., Bogdan, A., Legrand, J. C., and Desgrez, P. Aminoglutethimide and glutethimide: effects on 18-hydroxycorticosterone biosynthesis by human and sheep adrenals in vitro. Acta Endocrinol., 80:517-526,1975.
6. Dowsett, M., Harris, A. L., Stuart-Harris, R., Hill, M., Cantwell, B. K. J., Smith, I. E., and Jeffcoate, S. L. A comparison of the effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients. Br. J. Cancer, 52:525-529,1985.
7. Murray, R. M. L., and Pitt, P. Treatment of advanced metastatic breast cancer, carcinoma of the prostate, and endometrial cancer with aminoglutethimide. In: G. A. Nagel and R. J. Santen (eds.). Aminoglutethimide as an Aromatase Inhibitor in the Treatment of Cancer, pp. 109-122. Berne, Switzerland: Hans Huber, 1984.
8. Santen, R. J., Wells, S. A., Cohen, N., Demers, L. M., Misdn, R. 1., and Foltz, E. L. Compensatory increase in TSH secretion without effect on prolactin secretion in patients treated with aminoglutethimide. J. Qin. Endocrinol. Metab., 45:739-746,1977.
9. Stuart-Harris, R. C., and Smith, I. E. Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev., 11:189-204,1984.
10. Coombes, R. C., Goss, P., Dowsett, M., Gazet J. C., and Brodie, A. M. H. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet, 2:1237-1239,1984.
11. Dowsett M., Goss, P. E., Powles, T. J., Brodie, A. M. H., Jeffcoate, S. L., and Coombes, R. C. Use of the aromatase inhibitor 4-hydroxyandrostene-dione in postmenopausal breast cancer optimization of therapeutic dose and route. Cancer Res., 47:1957-1961,1987.
12. Brodie, A. M. H., Garrett W. M., Hendrickson, J. R., Tsai-Morris, C. H., Marcotte, P. A., and Robinson, C. H. Inactivation of aromatase in vitro by 4-hydroxyandrostenedione and 4-acetoxyandrostenedione and sustained effects in vivo. Steroids, 38:693-702,1981.
13. Goss, P. E., Powles, T. J., Dowsett, M., Hutchinson, G., Brodie, A. M. H., Gazet J. C., and Coombes, R. C. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: Phase II report. Cancer Res., 46:4823-4826,1986.
14. Cunningham, D., Powles, T. J., Dowsett, M., Hutchinson, G., Brodie, A.M.H., Ford, H. T., Gazet J. C., and Coombes, R. C. Oral 4-hydroxyandroste-nedione, a new endocrine treatment for disseminated breast cancer. Cancer Chemother. Pharmacol., 20:253-255,1987.
15. Hayward, J. L., Rubens, R. D., Carbone, P. P., Heuson, J-C., Kumablea, S., and Segaloff, A. Assessment of response to therapy in advanced breast cancer. Br. J. Cancer, 35:292-298,1977.
16. Ferguson, K., Hayes, M., and Jeffcoate, S. L. A standardized multicentre procedure for plasma gonadotrophin radioimmunoassay. Ann. Clin. Biochem., 19:358-361,1982.
17. Dowsett M., Attree, S. L., Virdee, S. S., and Jeffcoate, S. L. Oestrogen related changes in sex hormone binding globulin levels during normal and gonadotrophin-stimulated menstrual cycles. Clin. Endocrinol., 23:303-312, 1985.
18. Brodie, A. M. H., Romanoff, L. P., and Williams, K. I. H. Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione by male rhesus monkeys. J. Steroid Biochem., 14:693-696,1982.
19. Reiffsteck, A., Dehennin, L., and Scholler, R. Estrogens in seminal plasma of human and animal species: identification and quantitative estimation by gas chromatography-mass spectrometry associated with stable isotope dilution. J. Steroid Biochem., 17:567-572,1982.
20. Smith, I. E., Harris, A. L., Morgim, M., Gazet J-C., and MacKinna, J. A. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res. (Suppl.), 42:3430s-3433s, 1982.
21. Lipton, A., Harvey, H. A., Santen, R. J., Boucher, A., White, D., Bemath, A., Dixon, R., Richards, G., and Shafik, A. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res. (Suppl.), 42;3434s-3436s,1982.
22. Goss, P. E., Jarman, M., Wilkinson, J. R., and Coombes, R. C. Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a mgjor urinary metabolite in patients and biliary metabolite in the rat. J. Steroid Biochem., 24:619-622,1986.
23. Brodie, A. M. H., Brodie, H. J., Romanoff, L., Williams, J. G., Williams, K.I.H., and Wu, J. T. Inhibition of estrogen biosynthesis and regression of mammary tumours by aromatase inhibitors. Hormones Cancer Adv. Exp. Med. Biol., 138:179-190,1982.
24. Brodie, A. M. H., Schwarzel, W. C., Shaikh, A. A., and Brodie, H. J. The effect of an aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology, 100:1684-1695,1977.
25. Motta, M., Zoppi, S., Brodie, A. M. H., and Martin, L. Effect of 1,4,6-androstenedione-3,17-dione (ATD), 4-hydroxy-4-androstene-3,17-dione (4-OH-A) and 4-acetoxy-4-androstene-3,l 7-dione (4-Ac-A) on the 5 reduction of androgens in the rat prostate. J. Steroid Biochem., 25:593-600,1986.